A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

NCT07693777 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Hypertriglyceridemia (sHTG)
Hypertriglyceridemia

Interventions

BIOLOGICAL: DR10624 Injection
OTHER: Matching Placebo for DR10624

Sponsor

Zhejiang Doer Biologics Co., Ltd.